Cardiac risks associated with antibiotics: azithromycin and levofloxacin
- 10 December 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 14 (2), 295-303
- https://doi.org/10.1517/14740338.2015.989210
Abstract
Introduction: Azithromycin and levofloxacin have been shown to be efficacious in treating infections. The adverse drug events associated with azithromycin and levofloxacin were considered rare. However, the US FDA released warnings regarding the possible risk of QT prolongation with azithromycin and levofloxacin. Areas covered: Case reports/case series, observational studies and clinical trials assessing cardiovascular risks associated with azithromycin and levofloxacin were critically reviewed, including 15 case reports/series, 5 observational studies and 5 clinical trials that investigated the cardiac risks associated azithromycin and levofloxacin. Expert opinion: Results are discordant. Two retrospective studies utilizing large databases demonstrated an increased risk of cardiovascular death with azithromycin, when azithromycin was compared with amoxicillin. Two other retrospective studies found no difference in cardiovascular death associated with azithromycin and other antibiotics. For levofloxacin, the increased risk of cardiovascular death was only found in one retrospective study. Therefore, the risks and benefits of antibacterial therapies should be considered when making prescription decisions. This study should not preclude clinicians from avoiding azithromycin and levofloxacin. If a patient has an indication to receive an antibiotic and if azithromycin or levofloxacin is needed, it may be used, but the potential risks must be understood.Keywords
This publication has 63 references indexed in Scilit:
- Sudden Cardiac Arrest in a Patient on Chronic Methadone After the Addition of AzithromycinThe American Journal of the Medical Sciences, 2013
- Azithromycin and the Risk of Cardiovascular DeathThe New England Journal of Medicine, 2012
- Azithromycin for Prevention of Exacerbations of COPDThe New England Journal of Medicine, 2011
- The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockersCMAJ : Canadian Medical Association Journal, 2011
- Antimicrobials and the Risk of Torsades de PointesDrug Safety, 2010
- Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation Endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized ElectrocardiologyJournal of the American College of Cardiology, 2010
- Drug-Induced Prolongation of the QT IntervalThe New England Journal of Medicine, 2004
- Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trialThe Lancet, 2003
- Long QT syndromes and torsade de pointesThe Lancet, 1999
- Female gender as a risk factor for torsades de pointes associated with cardiovascular drugsJAMA, 1993